The Big Biotech reported top-line data from the studies in January. At that time, Vertex said its NaV1.8 inhibitor suzetrigine, then called VX-548, significantly improved pain intensity compared ...

Vertex has been developing inhibitors to the NaV1.8 sodium channel for many years and previously abandoned other candidates because they were not selective enough for the target and inhibited ...

Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and ...

Vertex’s approach is to selectively inhibit NaV1.8 using small molecules with the objective of creating a new class of pain signal inhibitors that have the potential to provide effective relief ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.38 per share for the third quarter of 2024, ...

led by povetacicept and AbbVie-partnered dual CD28 and ICOS inhibitor acazicolcept, which is in a phase 2 lupus trial, with results due later this year. Vertex has built its business on genetic ...

Analyst Whitney Ijem from Canaccord Genuity maintained a Sell rating on Vertex Pharmaceuticals (VRTX – Research Report) and decreased the ...

The 43 patients treated with ravulizumab had a 33.2% greater reduction in average urine protein to creatinine ratio (UPCR) ...

Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases.

Vertex is a global biotechnology company that ... and plans to continue to develop NaV1.8 and NaV1.7 inhibitors for both acute pain and PNP, (ix) expectations regarding the potential benefits ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...